3-chloro-3-methylbutylamine hydrochloride | 20213-85-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-chloro-3-methylbutylamine hydrochloride
• 英文别名: 3-Chloro-3-methylbutan-1-amine;hydrochloride；3-chloro-3-methylbutan-1-amine;hydrochloride
• CAS: 20213-85-8
• 化学式: C₅H₁₂ClN*ClH
• 分子量: 158.071
• InChiKey: ZVHDZAYGLCHNBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.77
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-azido-3-iodobicyclo[1.1.1]pentane 在 lithium aluminium tetrahydride 、 盐酸 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 24.0h， 以86%的产率得到3-chloro-3-methylbutylamine hydrochloride
  参考文献：
  名称：

  用氢化铝锂还原3-碘代双环[1.1.1]戊基叠氮化物的重排：中间体的机理证据。

  摘要：

  DOI：

  10.1021/jo001510e

文献信息

• QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS
  申请人：Courtney Stephen Martin

  公开号：US20110118258A1

  公开（公告）日：2011-05-19

  Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

  通式（I）的化合物；或其立体异构体、互变异构体、药学上可接受的盐或前药，其中R1、R2、R3、R4、R5、R6、R8和R9如本文所定义，对于治疗由过度或不恰当的Hsp90活性介导的疾病和病况，如癌症、病毒感染和炎症性疾病或病况，是有用的。
• [EN] NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES<br/>[FR] NOUVEAUX DÉRIVÉS PYRIMIDINES ET LEUR UTILISATION DANS LE TRAITEMENT D'UN CANCER ET AUTRES MALADIES
  申请人：ASTRAZENECA AB

  公开号：WO2010133885A1

  公开（公告）日：2010-11-25

  The invention concerns compounds of Formula (I): wherein L1, R1, R2, R3, R4 and X are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.

  该发明涉及式（I）的化合物：其中L1、R1、R2、R3、R4和X的定义如描述中所述。本发明还涉及制备这些化合物的方法，含有它们的药物组合物以及它们在治疗疾病（例如癌症）中的用途。
• Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
  申请人：——

  公开号：US20020198198A1

  公开（公告）日：2002-12-26

  The invention provides compounds which are PDE7inhibitors, having the following formula (I), (II) and (III) 1 in which X 1 , X 2 , X 3 , X 4 , X, Y, Z, A and Z 1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.

  本发明提供PDE7抑制剂化合物，具有以下公式（I），（II）和（III）：其中X1，X2，X3，X4，X，Y，Z，A和Z1如描述中所定义，制备它们的方法以及它们用于治疗需要PDE7抑制剂治疗的疾病的用途。
• [EN] NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS<br/>[FR] NOUVEAUX DERIVES SPIROTRICYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE-7
  申请人：WARNER LAMBERT CO

  公开号：WO2002074754A1

  公开（公告）日：2002-09-26

  The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III), in which X1, X2, X3, X4, X, Y, Z, A and Z1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.

  本发明提供了以下式子(I)、(II)和(III)的化合物，它们是PDE7抑制剂，其中X1、X2、X3、X4、X、Y、Z、A和Z1如描述中所定义，以及制备它们的方法和它们在治疗需要PDE7抑制剂治疗的疾病中的用途。
• New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
  申请人：Bernardelli Patrick

  公开号：US20070049558A1

  公开（公告）日：2007-03-01

  The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III) in which X 1 , X 2 , X 3 , X 4 , X, Y, Z, A and Z 1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.

  本发明提供了以下式子(I)、(II)和(III)的PDE7抑制剂化合物，其中X1、X2、X3、X4、X、Y、Z、A和Z1的定义如说明书中所述，以及制备它们的方法和它们用于治疗需要PDE7抑制剂治疗的疾病的用途。